Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment

2012 ◽  
Vol 24 (7) ◽  
pp. 2127-2132 ◽  
Author(s):  
A. D. Anastasilakis ◽  
S. A. Polyzos ◽  
P. Makras ◽  
A. Gkiomisi ◽  
M. Savvides ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Acid Treatment ◽  
Activin A ◽  
Low Bone Mass

Circulating Periostin Levels do not Differ Between Postmenopausal Women with Normal and Low Bone Mass and are not Affected by Zoledronic Acid Treatment

2013 ◽  
Vol 46 (02) ◽  
pp. 145-149 ◽  
Author(s):  
A. Anastasilakis ◽  
S. Polyzos ◽  
P. Makras ◽  
M. Savvides ◽  
G. Sakellariou ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Acid Treatment ◽  
Low Bone Mass

Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment

2014 ◽  
Vol 19 (3) ◽  
pp. 299-306 ◽  
Author(s):  
Athanasios D Anastasilakis ◽  
Stergios A Polyzos ◽  
Polyzois Makras ◽  
Athina Gkiomisi ◽  
Grigorios Sakellariou ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Low Bone Mass ◽  
Semaphorin 4D ◽  
Teriparatide Treatment

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass

2009 ◽  
Vol 114 (5) ◽  
pp. 999-1007 ◽  
Author(s):  
Michael McClung ◽  
Paul Miller ◽  
Chris Recknor ◽  
Peter Mesenbrink ◽  
Christina Bucci-Rechtweg ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Low Bone Mass ◽  
Prevention Of Bone Loss

scholarly journals Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial

2013 ◽  
Vol 98 (8) ◽  
pp. 3206-3212 ◽  
Author(s):  
Athanasios D. Anastasilakis ◽  
Stergios A. Polyzos ◽  
Athina Gkiomisi ◽  
Ilias Bisbinas ◽  
Spyridon Gerou ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Zoledronic Acid ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Low Bone Mass ◽  
Comparative Effect ◽  
Acid Versus ◽  
Dickkopf 1

scholarly journals Sclareol prevents ovariectomy-induced bone loss in vivo and inhibits osteoclastogenesis in vitro via suppressing NF-κB and MAPK/ERK signaling pathways

2019 ◽  
Vol 10 (10) ◽  
pp. 6556-6567 ◽  
Author(s):  
Haiming Jin ◽  
Zhenxuan Shao ◽  
Qingqing Wang ◽  
Jiansen Miao ◽  
Xueqin Bai ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Mass ◽  
Postmenopausal Women ◽  
Postmenopausal Osteoporosis ◽  
Bone Quality ◽  
Progressive Disease ◽  
Erk Signaling ◽  
Low Bone Mass

Postmenopausal osteoporosis (PMO) is a progressive disease occurring in elderly postmenopausal women that is characterized by low bone mass and impaired bone quality.

scholarly journals Expression of microRNAs that regulate bone turnover in the serum of postmenopausal women with low bone mass and vertebral fractures

2017 ◽  
Vol 176 (2) ◽  
pp. 169-176 ◽  
Author(s):  
Maria P Yavropoulou ◽  
Athanasios D Anastasilakis ◽  
Polyzois Makras ◽  
Dimitrios G Tsalikakis ◽  
Maria Grammatiki ◽  
...  
Keyword(s):  
Bone Mass ◽  
Postmenopausal Women ◽  
Vertebral Fractures ◽  
Patient Population ◽  
Group Analysis ◽  
Osteoporotic Fractures ◽  
Serum Levels ◽  
Low Bone Mass ◽  
Differential Expression Pattern ◽  
Novel Biomarkers

Background Circulating microRNAs (miRs) are currently being investigated as novel biomarkers for osteoporosis and osteoporotic fractures. Aim The aim of this study was to investigate serum levels of specific microRNAs, known regulators of bone metabolism, in postmenopausal women with low bone mass and with or without vertebral fractures (VFs). Methods For the analysis, 14 miRs were isolated from the serum of 35 postmenopausal women with low bone mass and with at least one moderate VF and 35 postmenopausal women with low bone mass without fractures. Thirty postmenopausal women with normal BMD values and no history of fractures served as controls. Main outcome parameters were changes in the expression of selected miRs in the serum of patient population and compared with controls. Results From the 14 miRs that were selected, we identified 5 miRs, namely miR-21-5p, miR-23a, miR-29a-3p, miR-124-3p and miR-2861 that were significantly deregulated in the serum of patients with low bone mass compared with controls. Serum miR-124 and miR-2861 were significantly higher, whereas miR-21, miR-23 and miR-29 were lower in patients compared with controls. In a sub-group analysis of the patient population, the expression of miR-21-5p was significantly lower among osteoporotic/osteopenic women with VFs, showing 66% sensitivity and 77% specificity in distinguishing women with a vertebral fracture. Conclusion This study identifies a differential expression pattern of miR-21-5p in the serum of women with low BMD and VFs.

Sign in / Sign up

Export Citation Format

Share Document